India to regulate phytopharmaceuticals but experts shy away from US route
This article was originally published in Scrip
Executive Summary
India has put out draft rules aimed at regulating phytopharmaceuticals in the country, setting out specifics in terms of trial and data requirements and on the manufacturing process.
You may also be interested in...
APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Opdivo Secures India Patent, Fends Off Multi-Party Opposition
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
Need a specific report? 1000+ reports available
Buy Reports